Lumbrokinase
Research reviewed: Up until 03/2026
Lumbrokinase (Lumbrokinase (earthworm fibrinolytic enzymes)) is a dietary supplement with 6 published peer-reviewed studies involving 426 participants, researched for Blood Clot Prevention, Cardiovascular Health, Stroke Prevention and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Blood Clot Prevention
StrongCardiovascular Health
ModerateStroke Prevention
ModerateFibrinolysis
WeakResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Blood Clot Prevention
To evaluate lumbrokinase supplementation on coagulation markers and platelet aggregation.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate lumbrokinase supplementation on coagulation markers and platelet aggregation.
Dose
600 mg/day lumbrokinase
Participants
80 patients with hypercoagulability states
Duration
12 weeks
Results
Lumbrokinase significantly reduced D-dimer, fibrinogen, and platelet aggregation rate compared to placebo. Lumbrokinase acts as a direct-acting fibrinolytic and thrombin inhibitor, reducing thrombotic risk.
How They Measured It
D-dimer, fibrinogen, platelet aggregation rate, PT, aPTT
To assess lumbrokinase versus aspirin for antiplatelet effects in high cardiovascular risk patients.
Study Type
Randomised, controlled trial
Purpose
To assess lumbrokinase versus aspirin for antiplatelet effects in high cardiovascular risk patients.
Dose
300 mg/day lumbrokinase vs 100 mg/day aspirin
Participants
120 patients with high cardiovascular risk
Duration
8 weeks
Results
Lumbrokinase produced comparable antiplatelet effects to aspirin without gastrointestinal side effects. P-selectin expression was significantly reduced in both groups. Lumbrokinase appears a viable aspirin alternative.
How They Measured It
Platelet aggregation, P-selectin expression, von Willebrand factor
Cardiovascular Health
To evaluate lumbrokinase on cardiovascular risk markers in patients with stable angina.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate lumbrokinase on cardiovascular risk markers in patients with stable angina.
Dose
600 mg/day lumbrokinase
Participants
140 patients with stable angina
Duration
6 months
Results
Lumbrokinase significantly reduced fibrinogen, CRP, and blood viscosity in stable angina patients. Angina frequency and nitroglycerine use were reduced, suggesting improved cardiovascular function.
How They Measured It
Fibrinogen, CRP, blood viscosity, quality of life
Stroke Prevention
To assess lumbrokinase as secondary prevention after ischaemic stroke.
Study Type
Randomised, controlled trial
Purpose
To assess lumbrokinase as secondary prevention after ischaemic stroke.
Dose
300 mg three times daily lumbrokinase
Participants
86 patients with history of ischaemic stroke
Duration
12 months
Results
Lumbrokinase added to standard therapy significantly reduced fibrinogen levels and was associated with lower recurrence of ischaemic events. Neurological recovery scores improved more in the lumbrokinase group.
How They Measured It
Recurrent stroke rate, neurological deficit scores, fibrinogen levels
To examine lumbrokinase on thrombus resolution in a rat carotid artery thrombosis model.
Study Type
Animal study
Purpose
To examine lumbrokinase on thrombus resolution in a rat carotid artery thrombosis model.
Dose
50 mg/kg oral lumbrokinase
Participants
Sprague-Dawley rats
Duration
24 hours
Results
Lumbrokinase significantly reduced thrombus weight and restored carotid blood flow in a dose-dependent manner. Effects were comparable to low-dose tissue plasminogen activator without associated bleeding risk.
How They Measured It
Thrombus weight, carotid blood flow restoration, fibrin clot imaging
Fibrinolysis
To characterise lumbrokinase's fibrinolytic enzyme components and activity.
Study Type
In-vitro study
Purpose
To characterise lumbrokinase's fibrinolytic enzyme components and activity.
Dose
Various lumbrokinase concentrations
Participants
Fibrin clot and plasma protein assays
Duration
N/A
Results
Lumbrokinase contains multiple serine protease enzymes capable of both direct fibrinolysis and activation of plasminogen to plasmin. Fibrinolytic activity is superior to nattokinase on a per-mg protein basis.
How They Measured It
Fibrin plate assay, casein degradation, zymography analysis
Frequently Asked Questions
Common questions about Lumbrokinase research
There are currently 6 peer-reviewed studies on Lumbrokinase (Lumbrokinase (earthworm fibrinolytic enzymes)), involving 426 total participants. Research covers Blood clot prevention, Cardiovascular health, Stroke prevention and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (4 human studies, 1 animal study), and reported outcomes.
Lumbrokinase has been researched for: Blood clot prevention, Cardiovascular health, Stroke prevention, Fibrinolysis. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 4 out of 6 studies are human trials. The remaining 1 is an animal study. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
